

25  
PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : <b>C07D 417/12, 413/12 A61K 31/42, 31/425, 31/41</b>		A1	(11) International Publication Number: <b>WO 93/21182</b> (43) International Publication Date: <b>28 October 1993 (28.10.93)</b>
(21) International Application Number: <b>PCT/GB93/00789</b> (22) International Filing Date: <b>14 April 1993 (14.04.93)</b>		(74) Agent: <b>THOMPSON, John; Merck &amp; Co., Inc., European Patent Department, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB).</b>	
(30) Priority data: <b>9208463.1 16 April 1992 (16.04.92) GB</b>		(81) Designated States: <b>AU, CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</b>	
(71) Applicant ( <i>for all designated States except US</i> ): <b>MERCK SHARP &amp; DOHME LIMITED [GB/GB]; Hertford Road, Hoddesdon, Hertfordshire EN11 9BU (GB).</b> (72) Inventors; and (75) Inventors/Applicants ( <i>for US only</i> ) : <b>CASTRO PINEIRO, Jose, Luis [ES/GB]; 92 The Hornbeams, Harlow, Essex CM20 1PQ (GB). MATASSA, Victor, Giulio [GB/GB]; The Duck Street Barns, Furneux Pelham, Hertfordshire SG9 0LA (GB).</b>		Published <i>With international search report.</i>	
(54) Title: <b>HETEROAROMATIC 5-HYDROXYTRYPTAMINE RECEPTOR AGONISTS</b>			
(57) Abstract <p>A class of substituted five-membered heteroaromatic compounds possessing an imino spacer group are selective agonists of 5-HT<sub>1</sub>-like receptors and are therefore useful in the treatment of clinical conditions, in particular migraine and associated disorders, for which a selective agonist of these receptors is indicated.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	CR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Mexico	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam


- 1 -

HETEROAROMATIC 5-HYDROXYTRYPTAMINE RECEPTOR AGONISTS

The present invention relates to a class of substituted five-membered heteroaromatic compounds possessing an imino spacer group. These compounds act on 5-hydroxytryptamine (5-HT) receptors, being selective agonists of so-called "5-HT<sub>1</sub>-like" receptors. They are therefore useful in the treatment of clinical conditions for which a selective agonist of these receptors is indicated.

5-HT<sub>1</sub>-like receptor agonists which exhibit selective vasoconstrictor activity have recently been described as being of use in the treatment of migraine (see, for example, A. Doenick *et al.*, *The Lancet*, 1988, Vol. 1, 1309-11). The compounds of the present invention, being selective 5-HT<sub>1</sub>-like receptor agonists, are accordingly of particular use in the treatment of migraine and associated conditions, e.g. cluster headache, chronic paroxysmal hemicrania, headache associated with vascular disorders, tension headache and paediatric migraine.

The present invention provides a compound of formula I, or a salt or prodrug thereof:



(I)

wherein the broken circle represents two non-adjacent double bonds in any position in the five-membered ring;


- 2 -

W, X, Y and Z independently represent oxygen, sulphur, nitrogen or carbon, provided that one of W, X, Y and Z represents oxygen or sulphur and at least one of W, X, Y and Z represents carbon;

5 A represents hydrogen, hydrocarbon, a heterocyclic group, halogen, cyano, trifluoromethyl,  $-OR^X$ ,  $-SR^X$ ,  $-NR^XRY$ ,  $-NR^XCOR^Y$ ,  $-NR^XCO_2RY$ ,  $-NR^XSO_2RY$ , or  $-NR^ZCTNR^XRY$ ;

10 E represents a bond or a straight or branched alkylene chain containing from 1 to 4 carbon atoms;


F represents a group of formula



20 U represents nitrogen or C-R<sup>2</sup>;

B represents oxygen, sulphur or N-R<sup>3</sup>;

R<sup>1</sup> represents  $-CH_2.CHR^4.NR^6R^7$  or a group of formula



in which the broken line represents an optional chemical bond;

- 3 -

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$  and  $R^7$  independently represent hydrogen or  $C_{1-6}$  alkyl;

5  $R^x$  and  $R^y$  independently represent hydrogen, hydrocarbon or a heterocyclic group, or  $R^x$  and  $R^y$  together represent a  $C_{2-6}$  alkylene group;

$R^z$  represents hydrogen, hydrocarbon or a heterocyclic group;

10  $T$  represents oxygen, sulphur or a group of formula  $=N.G$ ; and

15  $G$  represents hydrocarbon, a heterocyclic group or an electron-withdrawing group.

For use in medicine, the salts of the compounds of formula I will be non-toxic pharmaceutically acceptable salts. Other salts may, however, be useful in the preparation of the compounds according to the invention or of their non-toxic pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable non-toxic acid such as hydrochloric acid, sulphuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, oxalic acid, citric acid, 20 tartaric acid, carbonic acid or phosphoric acid. Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali metal salts, e.g. sodium or potassium salts; alkaline earth metal salts, e.g. calcium or magnesium salts; and salts formed with suitable organic ligands, e.g. quaternary ammonium salts.

30 The term "hydrocarbon" as used herein includes straight-chained, branched and cyclic groups containing up to 18 carbon atoms, suitably up to 15 carbon atoms,

- 4 -

and conveniently up to 12 carbon atoms. Suitable hydrocarbon groups include C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, C<sub>3-7</sub> cycloalkyl, C<sub>3-7</sub> cycloalkyl(C<sub>1-6</sub>)alkyl, aryl and aryl(C<sub>1-6</sub>)alkyl.

5        The expression "a heterocyclic group" as used herein includes cyclic groups containing up to 18 carbon atoms and at least one heteroatom preferably selected from oxygen, nitrogen and sulphur. The heterocyclic group suitably contains up to 15 carbon atoms and  
10      conveniently up to 12 carbon atoms, and is preferably linked through carbon. Examples of suitable heterocyclic groups include C<sub>3-7</sub> heterocycloalkyl, C<sub>3-7</sub> heterocycloalkyl(C<sub>1-6</sub>)alkyl, heteroaryl and heteroaryl(C<sub>1-6</sub>)alkyl groups.

15      Suitable alkyl groups include straight-chained and branched alkyl groups containing from 1 to 6 carbon atoms. Typical examples include methyl and ethyl groups, and straight-chained or branched propyl and butyl groups. Particular alkyl groups are methyl, ethyl and t-butyl.

20      Suitable alkenyl groups include straight-chained and branched alkenyl groups containing from 2 to 6 carbon atoms. Typical examples include vinyl and allyl groups.

25      Suitable alkynyl groups include straight-chained and branched alkynyl groups containing from 2 to 6 carbon atoms. Typical examples include ethynyl and propargyl groups.

30      Suitable cycloalkyl groups include groups containing from 3 to 7 carbon atoms. Particular cycloalkyl groups are cyclopropyl and cyclohexyl.

A particular aryl group is phenyl.

Particular aryl(C<sub>1-6</sub>)alkyl groups include benzyl, phenethyl and phenylpropyl.

- 5 -

Suitable heterocycloalkyl groups include azetidinyl, pyrrolidyl, piperidyl, piperazinyl and morpholinyl groups.

Suitable heteroaryl groups include pyridyl,  
5 quinolyl, isoquinolyl, pyridazinyl, pyrimidinyl,  
pyrazinyl, pyranyl, furyl, benzofuryl, dibenzofuryl,  
thienyl, benzthienyl, imidazolyl, oxadiazolyl and  
thiadiazolyl groups.

Particular heteroaryl(C<sub>1-6</sub>)alkyl groups include  
10 pyridylmethyl and pyrazinylmethyl.

The hydrocarbon and heterocyclic groups may in turn be optionally substituted by one or more groups selected from C<sub>1-6</sub> alkyl, adamantyl, phenyl, halogen, C<sub>1-6</sub> haloalkyl, C<sub>1-6</sub> aminoalkyl, trifluoromethyl, hydroxy, C<sub>1-6</sub> alkoxy, aryloxy, keto, C<sub>1-3</sub> alkylenedioxy, nitro, cyano, carboxy, C<sub>2-6</sub> alkoxycarbonyl, C<sub>2-6</sub> alkoxycarbonyl(C<sub>1-6</sub>)alkyl, C<sub>2-6</sub> alkylcarbonyloxy, arylcarbonyloxy, C<sub>2-6</sub> alkylcarbonyl, arylcarbonyl, C<sub>1-6</sub> alkylthio, C<sub>1-6</sub> alkylsulphinyl, C<sub>1-6</sub> alkylsulphonyl, arylsulphonyl, NR<sup>v</sup>R<sup>w</sup>, -NR<sup>v</sup>COR<sup>w</sup>, -NR<sup>v</sup>CO<sub>2</sub>R<sup>w</sup>,  
20 -NR<sup>v</sup>SO<sub>2</sub>R<sup>w</sup>, -CH<sub>2</sub>NR<sup>v</sup>SO<sub>2</sub>R<sup>w</sup>, -NHCONR<sup>v</sup>R<sup>w</sup>, -CONR<sup>v</sup>R<sup>w</sup>, -SO<sub>2</sub>NR<sup>v</sup>R<sup>w</sup> and -CH<sub>2</sub>SO<sub>2</sub>NR<sup>v</sup>R<sup>w</sup>, in which R<sup>v</sup> and R<sup>w</sup> independently represent hydrogen, C<sub>1-6</sub> alkyl, aryl or aryl(C<sub>1-6</sub>)alkyl, or R<sup>v</sup> and R<sup>w</sup> together represent a C<sub>2-6</sub> alkylene group.

When R<sup>x</sup> and R<sup>y</sup>, or R<sup>v</sup> and R<sup>w</sup>, together represent a C<sub>2-6</sub> alkylene group, this group may be an ethylene, propylene, butylene, pentamethylene or hexamethylene group, preferably butylene or pentamethylene.

When the group G represents an electron-withdrawing group, this group is suitably cyano, nitro, -COR<sup>x</sup>, -CO<sub>2</sub>R<sup>x</sup> or -SO<sub>2</sub>R<sup>x</sup>, in which R<sup>x</sup> is as defined above.

The term "halogen" as used herein includes fluorine, chlorine, bromine and iodine, especially fluorine.

- 6 -

The present invention includes within its scope prodrugs of the compounds of formula I above. In general, such prodrugs will be functional derivatives of the compounds of formula I which are readily convertible 5 in vivo into the required compound of formula I.

Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.


10 Where the compounds according to the invention have at least one asymmetric centre, they may accordingly exist as enantiomers. Where the compounds according to the invention possess two or more asymmetric centres, they may additionally exist as diastereoisomers. It is 15 to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention.

20 The five-membered heteroaromatic ring in formula I containing the substituents W to Z may be, for example, a furan, thiophene, oxazole, thiazole, isoxazole, isothiazole, oxadiazole or thiadiazole ring, in particular a 1,2,4-oxadiazole, 1,3,4-oxadiazole, 1,2,4-thiadiazole, 1,3,4-thiadiazole, 1,3-oxazole or 1,3-thiazole ring. Preferably the ring is a 1,2,4- 25 oxadiazole, 1,2,4-thiadiazole or 1,3,4-thiadiazole ring.


20 The alkylene chain E may be, for example, methylene, ethylene, 1-methylethylene, propylene or 2-methylpropylene. Alternatively, the group E may represent a single bond such that the group F in formula I is attached directly to the -NH- moiety, which in turn 30 is connected to the five-membered heteroaromatic ring.

The group F is suitably an indole, benzofuran or benzthiophene moiety of formula FA, or an indazole moiety of formula FB:

- 7 -




(FA)



(FB)

wherein B, R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are as defined above.

10 Preferably, the group F represents an indole moiety of structure FC:



(FC)

20 wherein R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are as defined above, in particular wherein R<sup>2</sup> and R<sup>3</sup> are both hydrogen.

Suitable values for the group A include C<sub>1-6</sub> alkyl, C<sub>3-7</sub> cycloalkyl, aryl, aryl(C<sub>1-6</sub>)alkyl, C<sub>3-7</sub> heterocycloalkyl, heteroaryl, heteroaryl(C<sub>1-6</sub>)alkyl, C<sub>1-6</sub> alkoxy or C<sub>1-6</sub> alkylthio, any of which groups may be optionally substituted; and hydrogen, halogen, cyano, trifluoromethyl or -NR<sup>x</sup>R<sup>y</sup>, in which R<sup>x</sup> and R<sup>y</sup> are as defined above. Examples of optional substituents on the group A suitably include trifluoromethyl, C<sub>1-6</sub> alkoxy, C<sub>2-6</sub> alkoxycarbonyl, C<sub>2-6</sub> alkylcarbonyl, C<sub>1-6</sub> alkylsulphonyl, arylsulphonyl, amino, mono- or di(C<sub>1-6</sub>)alkylamino, C<sub>2-6</sub> alkylcarbonylamino, arylcarbonylamino, C<sub>2-6</sub> alkoxycarbonylamino, C<sub>1-6</sub> alkylsulphonylamino, arylsulphonylamino, C<sub>1-6</sub> alkylsulphonylaminomethyl,

- 8 -

aminocarbonylamino, mono- or  
di(C<sub>1-6</sub>)alkylaminocarbonylamino, mono- or  
diarylaminocarbonylamino, pyrrolidylcarbonylamino,  
aminocarbonyl, mono- or di(C<sub>1-6</sub>)alkylaminocarbonyl, C<sub>1-6</sub>  
5 alkylaminosulphonyl, aminosulphonylmethyl, and mono- or  
di(C<sub>1-6</sub>)alkylaminosulphonylmethyl.

Particular values of A include hydrogen,  
methyl, methoxymethyl, aminomethyl, dimethylaminomethyl,  
acetylaminomethyl, benzoylaminomethyl, t-  
10 butoxycarbonylaminomethyl, methylsulphonylaminomethyl,  
phenylsulphonylaminomethyl, aminocarbonylmethyl, ethyl,  
aminoethyl, acetylaminoethyl, benzoylaminoethyl,  
methoxycarbonylamoethyl, ethoxycarbonylamoethyl,  
t-butoxycarbonylamoethyl, methylsulphonylamoethyl,  
15 aminocarbonylamoethyl, methylaminocarbonylamoethyl,  
t-butylaminocarbonylamoethyl, phenylaminocarbonyl-  
aminoethyl, pyrrolidylcarbonylamoethyl, cyclopropyl,  
phenyl, methylsulphonylaminophenyl, aminocarbonylphenyl,  
methylaminocarbonylphenyl, methylsulphonylaminomethyl-  
20 phenyl, aminosulphonylmethylphenyl, methylaminosulphonyl-  
methylphenyl, dimethylaminosulphonylmethylphenyl, benzyl,  
trifluoromethylbenzyl, methoxybenzyl, acetylaminobenzyl,  
methylsulphonylaminobenzyl, aminocarbonylaminobenzyl,  
aminocarbonylbenzyl, methylaminocarbonylbenzyl,  
25 methylsulphonylbenzyl, methylaminosulphonylbenzyl,  
pyridylmethyl, methoxypyridylmethyl, amino, methylamino,  
benzylamino, dimethylamino, t-butoxycarbonylamo-  
ethylamino and methylsulphonylaminethyleamino.


Preferred values of A include hydrogen, methyl,  
30 ethyl, benzyl and amino, especially methyl.

Representative values of R<sup>1</sup> include aminoethyl,  
N-methylaminoethyl, N,N-dimethylaminoethyl, 4-piperidyl,  
1-methyl-4-piperidyl, 3-pyrrolidinyl and 1-methyl-3-  
pyrrolidinyl.

- 9 -

Preferred values for the groups R<sup>2</sup> to R<sup>7</sup> are hydrogen and methyl.

A particular sub-class of compounds according to the invention is represented by the compounds of formula IIA, and salts and prodrugs thereof:



(IIA)

wherein

15        one of X<sup>1</sup> and Y<sup>1</sup> represents nitrogen and the other represents A<sup>1</sup>-C;  
           Z<sup>1</sup> represents oxygen or sulphur;  
           n is zero, 1, 2 or 3;  
           B<sup>1</sup> represents oxygen, sulphur or N-R<sup>13</sup>;

20        A<sup>1</sup> represents C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, C<sub>3-7</sub> cycloalkyl, aryl, aryl(C<sub>1-6</sub>)alkyl, C<sub>3-7</sub> heterocycloalkyl, heteroaryl, heteroaryl(C<sub>1-6</sub>)alkyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkylthio, C<sub>1-6</sub> alkylamino or di(C<sub>1-6</sub>)alkylamino, any of which groups may be optionally substituted; or hydrogen, halogen, cyano, trifluoromethyl or amino; and

25        R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>16</sup> and R<sup>17</sup> independently represent hydrogen or C<sub>1-6</sub> alkyl.

30        Examples of optional substituents on the group A<sup>1</sup> suitably include trifluoromethyl, C<sub>1-6</sub> alkoxy, C<sub>2-6</sub> alkoxycarbonyl, C<sub>2-6</sub> alkylcarbonyl, C<sub>1-6</sub> alkylsulphonyl, arylsulphonyl, amino, mono- or di(C<sub>1-6</sub>)alkylamino, C<sub>2-6</sub> alkylcarbonylamino, arylcarbonylamino, C<sub>2-6</sub> alkoxycarbonylamino, C<sub>1-6</sub> alkylsulphonylamino,

- 10 -

arylsulphonylamino, C<sub>1-6</sub> alkylsulphonylaminomethyl, aminocarbonylamino, mono- or di(C<sub>1-6</sub>)alkylamino-carbonylamino, mono- or diarylaminocarbonylamino, pyrrolidylcarbonylamino, aminocarbonyl, mono- or di(C<sub>1-6</sub>)alkylaminocarbonyl, C<sub>1-6</sub> alkylaminosulphonyl, aminosulphonylmethyl, and mono- or di(C<sub>1-6</sub>)alkylaminosulphonylmethyl.

Particular values of A<sup>1</sup> with respect to formula IIA include hydrogen, methyl, ethyl, benzyl and amino, especially methyl.

Preferably, R<sup>12</sup>, R<sup>13</sup> and R<sup>14</sup> each represents hydrogen. Preferred values of R<sup>16</sup> and R<sup>17</sup> with respect to formula IIA include hydrogen and methyl.

Specific compounds within the scope of the present invention include:

3-(2-aminoethyl)-5-[(3-methyl-1,2,4-thiadiazol-5-yl)aminomethyl]-1H-indole;  
3-[2-(dimethylamino)ethyl]-5-[(5-methyl-1,3,4-thiadiazol-2-yl)aminomethyl]-1H-indole;  
and salts and prodrugs thereof.

The invention also provides pharmaceutical compositions comprising one or more compounds of this invention in association with a pharmaceutically acceptable carrier. Preferably these compositions are in unit dosage forms such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, auto-injector devices or suppositories; for oral, parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation. For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose,

- 11 -

sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of a 5 compound of the present invention, or a non-toxic pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be 10 readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the 15 present invention. The tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, 20 the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A 25 variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.


30 The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils

- 12 -

such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone or gelatin.

In the treatment of migraine, a suitable dosage level is about 0.01 to 250 mg/kg per day, preferably about 0.05 to 100 mg/kg per day, and especially about 0.05 to 5 mg/kg per day. The compounds may be administered on a regimen of 1 to 4 times per day.


The compounds according to this invention wherein the group F is an indole moiety of structure FC as defined above may be prepared by a process which comprises reacting a compound of formula III:



(III)

wherein W, X, Y, Z, A and E are as defined above; with a compound of formula IV or a carbonyl-protected form thereof:

- 13 -



(IV)


wherein  $\text{R}^2$  is as defined above and  $\text{R}^{11}$  corresponds to the group  $\text{R}^1$  as defined above or represents a group of formula  $-\text{CH}_2\text{CHR}^4\text{D}^1$ , in which  $\text{R}^4$  is as defined above and  $\text{D}^1$  represents a readily displaceable group; followed, where required, by N-alkylation by standard methods to introduce the moiety  $\text{R}^3$ .

10 Suitable carbonyl-protected forms of the compounds of formula IV include the dimethyl acetal or 15 ketal derivatives.

20 The readily displaceable group  $\text{D}^1$  in the compounds of formula IV suitably represents a halogen atom, preferably chlorine. When the moiety  $\text{R}^{11}$  in the compounds of formula IV is a group of formula  $-\text{CH}_2\text{CHR}^4\text{D}^1$ , the substituent  $\text{D}^1$  is displaced in situ under the prevailing reaction conditions to afford a final product of formula I wherein  $\text{R}^1$  represents a group of formula  $-\text{CH}_2\text{CHR}^4\text{NH}_2$ . The terminal amino group can subsequently, if desired, be further elaborated using techniques known 25 from the art to give a compound of formula I wherein  $\text{R}^1$  represents the required group of formula  $-\text{CH}_2\text{CHR}^4\text{NR}^6\text{R}^7$ .

30 The reaction of compounds III and IV may be carried out in a single step (Fischer indole synthesis) or by an initial non-cyclising step at a lower temperature to give a compound of formula V:

- 14 -




(V)

10 wherein W, X, Y, Z, A, E, R<sup>2</sup> and R<sup>11</sup> are as defined above; followed by cyclisation using a suitable reagent, such as a polyphosphate ester.

The hydrazines of formula III may be prepared from the corresponding anilines of formula VI:

15




(VI)

wherein W, X, Y, Z, A and E are as defined above; by 25 diazotisation followed by reduction. Diazotisation is typically carried out using sodium nitrite/conc. HCl and the resulting diazo product reduced in situ using, for example, tin(II) chloride/conc. HCl, sodium sulphite/conc. HCl, or sodium sulphite/conc. H<sub>2</sub>SO<sub>4</sub>.

30 The anilines of formula VI may be prepared by reduction of the corresponding nitro compounds of formula VII:


- 15 -




(VII)

10 wherein W, X, Y, Z, A and E are as defined above;  
 typically by transfer hydrogenation using a hydrogenation catalyst such as palladium on charcoal in the presence of a hydrogen donor such as ammonium formate, or  
 alternatively by conventional catalytic hydrogenation or  
 15 using tin(II) chloride.

The nitro compounds of formula VII may be prepared by a variety of methods which will be readily apparent to those skilled in the art. One such method involves reacting an amino compound of formula VIII with  
 20 a compound of formula IX:



(VIII)



(IX)

30 wherein W, X, Y, Z, A and E are as defined above, and D<sup>2</sup> represents a readily displaceable group.


The reaction is conveniently carried out in the presence of sodium hydride using N,N-dimethylformamide as solvent.

- 16 -

The readily displaceable group D<sup>2</sup> in the compounds of formula IX is suitably a halogen atom, preferably bromine; except when the moiety D<sup>2</sup> is attached directly to the aromatic ring, i.e. when E represents a bond, in which case D<sup>2</sup> is preferably fluorine.

The compounds according to the invention wherein the group F is an indazole moiety of structure FB as defined above may be prepared by a process which comprises the cyclisation of a compound of formula X:

10




(X)

wherein W, X, Y, Z, A, E and R¹ are as defined above; and 20 D³ represents a readily displaceable group; followed, where required, by N-alkylation by standard methods to introduce the moiety R³.

The cyclisation of compound X is conveniently achieved in a suitable organic solvent at an elevated 25 temperature, for example in a mixture of m-xylene and 2,6-lutidine at a temperature in the region of 140°C.

The readily displaceable group D³ in the compounds of formula X suitably represents a C<sub>1-4</sub> alkanoyloxy group, preferably acetoxy. Where D³ in the 30 desired compound of formula X represents acetoxy, this compound may be conveniently prepared by treating a carbonyl compound of formula XI:

- 17 -




(XI)

10 wherein W, X, Y, Z, A, E and R<sup>1</sup> are as defined above; or  
 a protected derivative thereof; with hydroxylamine hydrochloride, advantageously in pyridine at the reflux temperature of the solvent; followed by acetylation with acetic anhydride, advantageously in the presence of a  
 15 catalytic quantity of 4-dimethylaminopyridine, in dichloromethane at room temperature.

The N-formyl protected derivative of the intermediate of formula XI may be conveniently prepared by ozonolysis of an indole derivative of formula XII:

20



(XII)


wherein W, X, Y, Z, A, E and R<sup>1</sup> are as defined above;  
 30 followed by a reductive work-up, advantageously using dimethylsulphide.

The indole derivative of formula XII may be prepared by methods analogous to those described in the

- 18 -

accompanying Examples, or by procedures well known from the art.

5 In an alternative process, the compounds according to the invention may be prepared by a method which comprises reacting a compound of formula XIII:



(XIII)

15 wherein W, X, Y, Z and A are as defined above, and L represents a suitable leaving group; with a compound of formula  $\text{H}_2\text{N}-\text{E}-\text{F}$ , in which E and F are as defined above.

20 The reaction is conveniently carried out in the presence of an organic base such as diisopropylamine or diisopropylethylamine, in a suitable solvent such as 2-ethoxyethanol or tetrahydrofuran, advantageously at the reflux temperature of the reaction mixture.


The leaving group L suitably represents halogen, e.g. chlorine, or a nitro group.

25 In further process, the compounds according to the invention in which E is other than a chemical bond may be prepared by reacting a compound of formula  $\text{OHC}-\text{E}'-\text{F}$ , wherein F is as previously defined and E' represents a bond or a straight or branched alkylene chain containing from 1 to 3 carbon atoms; with a compound of formula VIII as defined above; followed by treatment with a reducing agent. The resulting product is a compound of formula I as defined above in which the group E is represented by a moiety of formula  $-\text{CH}_2\text{E}'-$ .

- 19 -

The above reaction is advantageously carried out in two stages. In the first stage, the reagents are suitably heated together under reflux, with removal of water, in a suitable solvent such as toluene, optionally in the presence of a protic solvent such as ethanol. Removal of water is conveniently effected by standard means such as by the utilisation of 3A molecular sieves, or in a Dean-Stark apparatus. In the second stage, the product obtained from the first stage is treated, preferably crude, with a reducing agent, advantageously in an alcoholic solvent such as methanol. A preferred reducing agent for use in this process is sodium borohydride.

In a yet further process, the compounds according to the invention wherein the group F is a benzofuran or benzthiophene moiety may be prepared by a method which comprises cyclising a compound of formula XIV:




(XIV)

wherein W, X, Y, Z, A, E and R<sup>2</sup> are as defined above, B<sup>a</sup> represents oxygen or sulphur, and R<sup>21</sup> corresponds to the group R<sup>1</sup> as defined above or represents a precursor group thereto as discussed below; followed, where required, by conversion of the group R<sup>21</sup> into the desired group R<sup>1</sup> by conventional means.


- 20 -

The cyclisation is conveniently effected by using polyphosphoric acid or a polyphosphate ester, advantageously at an elevated temperature.

5 The compounds of formula XIV may be prepared by reacting a compound of formula XV with a compound of formula XVI:



(XV)




(XVI)

15 wherein W, X, Y, Z, A, E, B<sup>a</sup>, R<sup>2</sup> and R<sup>21</sup> are as defined above, and Hal represents halogen.

The reaction is conveniently effected in the presence of a base such as sodium hydroxide.

20 The hydroxy and mercapto derivatives of formula XV may be prepared by a variety of methods which will be readily apparent to those skilled in the art. In one such method, a compound of formula VIII as defined above is reacted with a compound of formula XVII:



(XVII)

wherein D<sup>2</sup>, E and B<sup>a</sup> are as defined above.

Where they are not commercially available, the intermediates of formula IV, VIII, IX, XIII, XVI, XVII,

- 21 -

$\text{H}_2\text{N}-\text{E}-\text{F}$  and  $\text{OHC}-\text{E}'-\text{F}$  referred to above may be prepared by methods analogous to those described hereinafter for the preparation of Intermediates 1 to 3; or by procedures known from the art.

5        It will be understood that any compound of formula I initially obtained from any of the above processes may, where appropriate, subsequently be elaborated into a further compound of formula I by techniques known from the art. In particular, a compound of formula I wherein  $\text{R}^3$  is hydrogen initially obtained may be converted into a compound of formula I wherein  $\text{R}^3$  represents  $\text{C}_{1-6}$  alkyl by standard alkylation techniques, for example by treatment with an alkyl iodide, e.g. methyl iodide, typically under basic conditions, e.g. sodium hydride in dimethylformamide. Similarly, a compound of formula I wherein  $\text{R}^1$  represents a group of formula  $-\text{CH}_2\text{.CHR}^4\text{.NH}_2$  initially obtained may be converted into a compound of formula I wherein  $\text{R}^1$  represents a group of formula  $-\text{CH}_2\text{.CHR}^4\text{.NR}^6\text{R}^7$  in which  $\text{R}^6$  and  $\text{R}^7$  independently represent  $\text{C}_{1-6}$  alkyl, by conventional N-alkylation techniques, e.g. by treatment with the appropriate aldehyde in the presence of a reducing agent such as sodium cyanoborohydride.

25      Where the above-described processes for the preparation of the compounds according to the invention give rise to mixtures of stereoisomers, these isomers may be separated by conventional techniques such as preparative chromatography.

30      The novel compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution. The novel compounds may, for example, be resolved into their component enantiomers by standard techniques, such as the formation of diastereomeric pairs by salt formation with

an optically active acid, such as (-)-di-p-toluoyl-d-tartaric acid and/or (+)-di-p-toluoyl-l-tartaric acid followed by fractional crystallization and regeneration of the free base. The novel compounds may also be 5. resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary.

During any of the above synthetic sequences it 10. may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene & P.G.M. Wuts, Protective Groups in 15. Organic Synthesis, John Wiley & Sons, 1991. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.

Alternatively, certain of the functional groups 20. on the desired products may be carried through the reaction sequence as precursor groups, and then regenerated from these precursor groups at a late stage in the overall synthesis. For example, where R<sup>1</sup> in the desired compound of formula I represents a group of formula -(CH<sub>2</sub>)<sub>2</sub>NH<sub>2</sub>, this group can be generated from a 25. cyano precursor -CH<sub>2</sub>CN by reduction using, for example, borane/tetrahydrofuran. The cyano precursor may in turn be carried through the reaction sequence as a methyl group -CH<sub>3</sub>, which may conveniently be converted to -CH<sub>2</sub>CN by treatment with N-bromosuccinimide and benzoyl 30. peroxide, in the presence of a bright light source, followed by reaction of the resulting bromo intermediate with sodium cyanide in dimethyl sulphoxide.

The following Examples illustrate the preparation of compounds according to the invention.

- 23 -

The ability of test compounds to bind to 5-HT<sub>1</sub>-like receptors was measured in membranes prepared from pig caudate using the procedure described in J. Neurosci., 1987, 7, 894. Binding was determined using 5 2 nM 5-hydroxytryptamine creatinine sulphate, 5-[1,2-<sup>3</sup>H(N)] as a radioligand. Cyanopindolol (100 nM) and mesulergine (100 nM) were included in the assay to block out 5-HT<sub>1A</sub> and 5-HT<sub>1C</sub> binding sites respectively. The concentration of the compounds of the accompanying 10 Examples required to displace 50% of the specific binding (IC<sub>50</sub>) is below 1  $\mu$ M in each case.

The activity of test compounds as agonists of the 5-HT<sub>1</sub>-like receptor was measured in terms of their ability to mediate contraction of the saphenous vein of 15 New Zealand White rabbits, using the procedure described in Arch. Pharm., 1990, 342, 111. Agonist potencies were calculated as -log<sub>10</sub>EC<sub>50</sub> (pEC<sub>50</sub>) values, from plots of percentage 5-HT (1  $\mu$ M) response against the concentration of the agonist. The compounds of the accompanying 20 Examples were found to possess pEC<sub>50</sub> values in this assay of not less than 5.0 in each case.

INTERMEDIATE 13-[2-(Dimethylamino)ethyl]-1H-indole-5-carboxaldehyde5      1. 4-Cyanophenylhydrazine. Hydrochloride

To a cooled (-15°C) and stirred suspension of 4-aminobenzonitrile (50g, 423mmol) in concentrated hydrochloric acid (550ml) was added dropwise a solution of sodium nitrite (31.5g, 457mmol) in water (200ml) at such a rate as to maintain the temperature below -10°C. After the addition was finished, the reaction mixture was quickly filtered to remove solids and the filtrate was added portionwise to a cooled (-20°C) and stirred solution of tin (II) chloride dihydrate (477g, 2.1mol) in concentrated hydrochloric acid (370ml) at such a rate as to maintain the temperature below -10°C. After further 15 minutes at -10°C to 0°C, the white precipitate was collected by filtration, washed with diethyl ether (4 x 250ml) and dried to give 56g (78%) of the title compound; mp 235-237°C (ethanol-water 1:1);  
20       $\delta_{\text{H}}$  (250MHz, DMSO-d<sub>6</sub>) 10.50 (3H, br s, -N<sup>+</sup>H<sub>3</sub>), 9.10 (1H, br s, -NH-), 7.71 (2H, d, J = 8.8Hz, Ar-H), 7.03 (2H, d, J = 8.8Hz, Ar-H); m/z (CI) 132 (M<sup>+</sup>-1).

25      2. 3-(2-Aminoethyl)-5-cyano-1H-indole. Hydrochloride

To a stirred suspension of 4-cyanophenylhydrazine hydrochloride (50g) in a mixture of ethanol and water (5:1; 2l) was added 4-chlorobutanal dimethylacetal (45g) and the resulting mixture was refluxed for 18 hours. Solvents were removed under vacuum and the residue was azeotroped with toluene to give a brown solid. Crystallisation of this crude material from methanol (150ml) gave 23g (35%) of the title compound as a yellow solid; mp 270-274°C;  $\delta_{\text{H}}$  (250MHz,

- 25 -

DMSO-d<sub>6</sub>) 11.60 (1H, br s, indole N-H), 8.17 (1H, d, J = 1.1Hz, Ar-H), 7.97 (3H, br s, -N<sup>+</sup>H<sub>3</sub>), 7.54 (1H, d, J = 8.5Hz, Ar-H), 7.46 (1H, s, Ar-H), 7.44 (1H, dd, J = 8.5 and 1.1Hz, Ar-H), 3.05 (4H, br s, -CH<sub>2</sub>CH<sub>2</sub>N-); m/z (CI) 184 (M<sup>+</sup>-1).

5

**3. 5-Cyano-3-[2-(dimethylamino)ethyl]-1H-indole**

To a cooled (5°C) and stirred solution of sodium methoxide in anhydrous methanol (from 1.75g of sodium metal in 400ml of methanol) was added 3-(2-aminoethyl)-5-cyano-1H-indole hydrochloride (18.6g) and the mixture was stirred for a further 5 minutes before sodium cyanoborohydride (7.2g) and glacial acetic acid (10.4ml) were added. A solution of formaldehyde (37% aqueous solution; 19.9ml) in methanol (50ml) was added dropwise over 30 minutes and the mixture was then allowed to warm to room temperature and stirred for a further 15 minutes. Solvents were removed under vacuum and the residue was diluted with saturated aqueous potassium carbonate (400ml) and products were extracted with ethyl acetate (3 x 400ml). The combined organic extracts were dried (MgSO<sub>4</sub>) and concentrated. Flash chromatography of the residue (silica gel, dichloromethane-methanol-ammonia, 40:8:1) gave 10.5g of the title compound as a pale yellow solid; δ<sub>H</sub> (250MHz, CDCl<sub>3</sub>) 8.60 (1H, br s, indole N-H), 7.94 (1H, d, J = 1.5Hz, Ar-H), 7.39 (1H, dd, J = 8.5 and 1.5Hz, Ar-H), 7.13 (1H, br d, Ar-H), 2.94 (2H, m, -CH<sub>2</sub>-), 2.66 (2H, m, -CH<sub>2</sub>-), 2.35 (6H, s, -NMe<sub>2</sub>); m/z (FAB) 212 (M<sup>+</sup>-1).

10

15

20

25

30

**4. 3-[2-(Dimethylamino)ethyl]-1H-indole-5-carboxaldehyde**

To a solution of the product from step 3 (10.5g) in a mixture of water, acetic acid and pyridine (1:1:2; 600ml) were added sodium hypophosphite hydrate (20.6g) and Raney nickel

- 26 -

(50% slurry in water; 5.0g) and the mixture was stirred at 40°C for 24 hours under nitrogen. After being cooled to room temperature, the mixture was filtered and solvents were removed under vacuum. The remaining residue was dissolved in water (300ml), basified to pH 10 with solid potassium carbonate and products were extracted with dichloromethane (3 x 300ml), dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated to give the title compound (8.6g) as a pale yellow solid; δ<sub>H</sub> (360MHz, CDCl<sub>3</sub>) 10.04 (1H, s, -CHO), 8.6 (1H, br s, indole N-H), 8.15 (1H, br s, Ar-H), 7.73 (1H, dd, J = 8.5 and 1.4Hz, Ar-H), 7.38 (1H, d, J = 8.5Hz, Ar-H), 7.11 (1H, br s, Ar-H), 3.00 (2H, t, J = 8.2Hz, -CH<sub>2</sub>-), 2.69 (2H, t, J = 8.2Hz, -CH<sub>2</sub>-), 2.36 (6H, s, -NMe<sub>2</sub>).

#### INTERMEDIATE 2

15

##### 1-tert-Butyloxycarbonyl-3-[2-(dimethylamino)ethyl]-indole -5- carboxaldehyde

20 To a solution of Intermediate 1 (8.4g, 39mmol) in anhydrous acetonitrile (150ml) was added di-tert-butyldicarbonate (12.7g, 58mmol) followed by 4-dimethylaminopyridine (476mg, 3.9mmol) and the resulting mixture was stirred for two hours at room temperature under nitrogen. Solvents were removed under vacuum and the residue was purified by flash chromatography (silica gel, dichloromethane-methanol-ammonia, 90:10:1) to give 10.5g (83%) of the title compound as a viscous oil; δ<sub>H</sub> (250MHz, CDCl<sub>3</sub>) 10.08 (1H, s, -CHO), 8.25 (1H, d, J = 8.6Hz, Ar-H), 8.07 (1H, d, J = 1.5Hz, Ar-H), 7.83 (1H, dd, J = 8.6 and 1.5Hz, Ar-H), 7.50 (1H, s, Ar-H), 2.93 (2H, m, -CH<sub>2</sub>-), 2.67 (2H, m, -CH<sub>2</sub>-), 2.34 (6H, s, -NMe<sub>2</sub>), 1.68 (9H, s, t-Bu).

INTERMEDIATE 35-Aminomethyl-3-[2-(N-tert-butyloxycarbonylamino)ethyl]-1H-indole

5

1. 3-[2-(N-tert-Butyloxycarbonylamino)ethyl]-5-cyano-1H-indole

10 To a cooled (-20°C) and stirred suspension of 3-(2-aminoethyl)-5-cyano-1H-indole hydrochloride (15g, 68mmol) in anhydrous dichloromethane (500ml) and anhydrous triethylamine (13.7g, 136mmol) was added di-tert-butyldicarbonate (19.3g, 88mmol). After being stirred at -20°C for 0.5 hours and at room temperature for 1.5 hours, the 15 reaction mixture was diluted with dichloromethane (300ml), washed with 2N hydrochloric acid (300ml), brine (300ml), dried ( $\text{Na}_2\text{SO}_4$ ) and concentrated. Flash chromatography of the residue (silica gel, dichloromethane-methanol, 96:4) gave 11.3g of the title compound as a white solid; mp 132-134°C (hexane-ethyl acetate);  $\delta_{\text{H}}$  (250MHz,  $\text{CDCl}_3$ ) 8.42 (1H, br s, indole N-H), 7.93 (1H, s, Ar-H), 7.41 (2H, s, Ar-H), 7.12 (1H, d,  $J$  = 2.2Hz, Ar-H), 4.71 (1H, br s, -NH-), 3.44 (2H, q,  $J$  = 6.9Hz, - $\text{CH}_2\text{NH}-$ ), 2.94 (2H, t,  $J$  = 6.9Hz, Ar- $\text{CH}_2-$ ), 1.45 (9H, s, t-Bu); m/z (CI) 286 ( $\text{M}^++1$ ).

20

25 2. 5-Aminomethyl-3-[2-(N-tert-butyloxycarbonylamino)ethyl-1H-indole

30 A solution of the product from the previous step (11.3g) in a mixture of absolute ethanol (750ml) and chloroform (22ml) was hydrogenated at 50 psi over platinum (IV) oxide (1g) for 28 hours. The catalyst was removed by filtration and solvents were removed under vacuum. Flash chromatography of the residue (silica gel, dichloromethane-methanol-ammonia, 90:10:1) gave

- 28 -

9.5g (82%) of the title compound as a white solid; mp 147-149°C  
ethyl acetate-diethyl ether);  $\delta_{\text{H}}$  (360MHz,  $\text{CDCl}_3$ ) 8.04 (1H, br s, indole N-H), 7.52 (1H, s, Ar-H), 7.33 (1H, d,  $J$  = 8.4Hz, Ar-H), 7.16 (1H, d,  $J$  = 8.4Hz, Ar-H), 7.03 (1H, s, Ar-H), 4.61 (1H, br s, -NHBOC), 3.96 (2H, s, Ar- $\text{CH}_2\text{NH}_2$ ), 3.45 (2H, br q, - $\text{CH}_2\text{NHBOC}$ ), 2.95 (2H, t,  $J$  = 6.8Hz, Ar- $\text{CH}_2-$ ), 1.43 (9H, s, t-Bu); m/z (CI) 288 ( $\text{M}^+-1$ ).

EXAMPLE 1

10 3-(2-Aminoethyl)-5-[(3-methyl-1,2,4-thiadiazol-5-yl)amino  
methyll-1H-indole. Oxalate

1. 3-[2-(tert-Butyloxycarbonylamino)ethyl]-5-[(3-methyl-  
1,2,4-thiadiazol-5-yl)aminomethyl-1H-indole

15 To a stirred solution of Intermediate 3 (500mg, 1.72mmol) in anhydrous tetrahydrofuran (8ml) and anhydrous diisopropylethylamine (0.30ml) was added 5-chloro-3-methyl-1,2,4-thiadiazole (403mg, 3.0mmol) and the mixture was refluxed for 24 hours under nitrogen. After being cooled to room temperature, water (10ml) was added and products were extracted with dichloromethane (3 x 30ml), then dried ( $\text{Na}_2\text{SO}_4$ ) and concentrated. Flash chromatography of the residue (silica gel, hexane-ethyl acetate, 40:60) gave 263mg (43%) of the title compound as a white solid;  $\delta_{\text{H}}$  (250MHz,  $\text{CDCl}_3$ ) 8.17 (1H, br s, indole N-H), 7.56 (1H, s, Ar-H), 7.35 (1H, d,  $J$  = 8.3Hz, Ar-H), 7.17 (1H, dd,  $J$  = 1.3 and 1.4Hz, Ar-H), 7.06 (1H, d,  $J$  = 2.2Hz, Ar-H), 6.35 (1H, br s, -NH-), 4.62 (1H, br s, -NHBOC), 4.51 (2H, d,  $J$  = 4.0Hz, Ar- $\text{CH}_2\text{-N}$ ), 3.42 (2H, m, - $\text{CH}_2\text{NHBOC}$ ), 2.93 (2H, t,  $J$  = 6.9Hz, Ar- $\text{CH}_2-$ ), 2.38 (3H, s, -Me), 1.43 (9H, s, t-Bu); m/z (FAB<sup>+</sup>) 386 ( $\text{M}^+-1$ ).

- 29 -

2. 3-(2-Aminoethyl)-5-[3-methyl-1,2,4-thiadiazol-5-yl)aminomethyl-1H-indole. Oxalate

A solution of the product from the previous step (105mg) in  
5 anhydrous dichloromethane (2ml) and trifluoroacetic acid (0.6ml)  
was stirred under nitrogen for 1 hour. Solvents were removed  
under vacuum and the remaining residue was purified by flash  
chromatography (silica gel, dichloromethane-  
methanol-ammonia, 85:15:1) to give 75mg of the title compound  
10 free base as a white solid. The oxalate salt was prepared; mp  
121-123°C (methanol-diethyl ether);  $\delta_H$  (250MHz, DMSO-d<sub>6</sub>)  
15 10.98 (1H, s, indole N-H), 8.76 (1H, br s, -NH-), 7.52 (1H, s,  
Ar-H), 7.35 (1H, d, J = 8.3Hz, Ar-H), 7.24 (1H, d, J = 2.1Hz,  
Ar-H), 7.09 (1H, dd, J = 8.3 and 1.5Hz, Ar-H), 4.52 (2H, s,  
Ar-CH<sub>2</sub>-N), 3.06 (2H, m, -CH<sub>2</sub>-), 2.98 (2H, m, -CH<sub>2</sub>-), 2.25 (6H, s,  
-NMe<sub>2</sub>); m/z (CI) 288 (M<sup>+</sup>+1). (Found: C, 50.68; H, 5.08; N, 17.69.  
C<sub>14</sub>H<sub>17</sub>N<sub>5</sub>S x 1.1 C<sub>2</sub>H<sub>2</sub>O<sub>4</sub> x 0.1 C<sub>4</sub>H<sub>10</sub>O requires: C, 50.63; H, 5.17;  
N, 17.78%).

20

EXAMPLE 2

3-[2-(Dimethylamino)ethyl]-5-[5-methyl-1,3,4-thiadiazol-2-yl)aminomethyl-1H-indole. Oxalate

1. 1-tert-Butyloxycarbonyl-3-[2-dimethylamino)ethyl-5-[5-methyl-1,3,4-thiadiazol-2-yl)aminomethyl-indole

25

A mixture of Intermediate 2 (225mg, 0.71mmol),  
2-amino-5-methyl-1,3,4-thiadiazole (123mg, 1.07mmol) and  
p-toluenesulfonic acid (12mg) in anhydrous toluene (10ml) was  
refluxed, using a Dean-Stark trap, for 4.5 hours under nitrogen.  
30 The toluene was removed under vacuum and the residue was  
dissolved in anhydrous methanol (10ml) and treated with solid

- 30 -

sodium borohydride (400mg) over 1 hour. After further 15 hours of stirring at room temperature, the solvent was removed under vacuum and the residue dissolved in 2N hydrochloric acid (10ml) and then basified with 2N sodium hydroxide. Products were extracted with ethyl acetate (4 x 40ml), washed with brine (1 x 15ml), dried ( $MgSO_4$ ) and concentrated. Flash chromatography of the residue (silica gel, dichloromethane-methanol-ammonia, 92:8:0.8; and dichloromethane-methanol, 88:12 to dichloromethane-methanol-ammonia, 90:10:1) gave 165mg (56%) of the title compound as a colourless thick oil;  $\delta_H$  (250MHz,  $CDCl_3$ ) 8.08 (1H, d,  $J$  = 8.3Hz, Ar-H), 7.51 (1H, d,  $J$  = 1.6Hz, Ar-H), 7.41 (1H, s, Ar-H), 7.30 (1H, dd,  $J$  = 8.3 and 1.6Hz, Ar-H), 5.48 (1H, br s, -NH-), 4.60 (2H, s, Ar- $CH_2$ -N), 2.85 (2H, m, - $CH_2$ -), 2.61 (2H, m, - $CH_2$ -), 2.56 (3H, s, -Me), 2.33 (6H, s, - $NMe_2$ ), 1.66 (9H, s, t-Bu); m/z (CI) 416 ( $M^+ + 1$ ).

2. 3-[2-(Dimethylamino)ethyl]-5-[(5-methyl-1,3,4-thiadiazol-2-yl)aminomethyl]-1H-indole. Oxalate

20 A solution of the product from the previous step (160mg) in a mixture of dichloromethane (16ml), trifluoroacetic acid (4ml) and water (0.5ml) was allowed to stand at room temperature for 2.5 hours under nitrogen. Solvents were removed under vacuum and the residue was azeotroped with methanol (1 x 10ml) before it was dissolved in saturated aqueous potassium carbonate (10ml) and products were extracted with ethyl acetate (2 x 40ml). The combined organic solutions were washed with brine (1 x 10ml), dried ( $MgSO_4$ ) and concentrated. Flash chromatography of the residue (silica gel, dichloromethane-methanol-ammonia, 85:15:1.5) gave 95mg (78%) of the title compound free base as a colourless thick oil. The oxalate salt was prepared and recrystallised from a mixture of ethanol and methanol; mp 207-209°C;  $\delta_H$  (360MHz,  $DMSO-d_6$ ) 10.95 (1H, s, indole N-H),

- 31 -

7.96 (1H, br s, -NH-), 7.57 (1H, s, Ar-H), 7.33 (1H, d, J = 8.3Hz, Ar-H), 7.23 (1H, s, Ar-H), 7.11 (1H, d, J = 8.3Hz, Ar-H), 4.49 (2H, s, Ar-CH<sub>2</sub>-N), 3.26 (2H, m, -CH<sub>2</sub>-), 3.05 (2H, m, -CH<sub>2</sub>-), 2.80 (6H, s, -NMe<sub>2</sub>), 2.43 (3H, s, -Me); m/z (CI) 315 (M<sup>+</sup>). (Found: C, 51.57; H, 5.63; N, 16.35. C<sub>16</sub>H<sub>21</sub>N<sub>5</sub>S x 1.3 C<sub>2</sub>H<sub>2</sub>O<sub>4</sub> requires: C, 51.66; H, 5.50; N, 16.19%).

5

### EXAMPLE 3

10

#### Tablet Preparation

Tablets containing 1.0, 2.0, 25.0, 26.0, 50.0 and 100.0mg, respectively of the following compounds are prepared as illustrated below:

15

3-(2-Aminoethyl)-5-[(3-methyl-1,2,4-thiadiazol-5-yl)amino methyl]-1H-indole. Oxalate

3-[2-(Dimethylamino)ethyl]-5-[(5-methyl-1,3,4-thiadiazol-2-yl) aminomethyl]-1H-indole. Oxalate

- 32 -

TABLE FOR DOSES CONTAINING FROM  
1-25MG OF THE ACTIVE COMPOUND

	Amount-mg		
5	Active Compound	1.0	2.0
	Microcrystalline cellulose	49.25	48.75
	Modified food corn starch	49.25	48.75
	Magnesium stearate	0.50	0.50
		25.0	37.25

10 TABLE FOR DOSES CONTAINING FROM  
26-100MG OF THE ACTIVE COMPOUND

15	Active Compound	26.0	50.0	100.0
	Microcrystalline cellulose	52.0	100.0	200.0
	Modified food corn starch	2.21	4.25	8.5
	Magnesium stearate	0.39	0.75	1.5


20 All of the active compound, cellulose, and a portion of the corn starch are mixed and granulated to 10% corn starch paste. The resulting granulation is sieved, dried and blended with the remainder of the corn starch and the magnesium stearate. The resulting granulation is then compressed into tablets containing 1.0mg, 2.0mg, 25.0mg, 26.0mg, 50.0mg and 100mg of the active ingredient per tablet.

25

- 33 -

CLAIMS:

1. A compound of formula I, or a salt or  
 5 prodrug thereof:



(I)


15 wherein the broken circle represents two non-adjacent double bonds in any position in the five-membered ring;

W, X, Y and Z independently represent oxygen, sulphur, nitrogen or carbon, provided that one of W, X, Y and Z represents oxygen or sulphur and at least one of W, X, Y and Z represents carbon;

20 A represents hydrogen, hydrocarbon, a heterocyclic group, halogen, cyano, trifluoromethyl,  $-OR^x$ ,  $-SR^x$ ,  $-NR^xR^y$ ,  $-NR^xCOR^y$ ,  $-NR^xCO_2R^y$ ,  $-NR^xSO_2R^y$ , or  $-NR^zCTNR^yR^z$ ;

25 E represents a bond or a straight or branched alkylene chain containing from 1 to 4 carbon atoms;


F represents a group of formula



- 34 -

U represents nitrogen or C-R<sup>2</sup>;  
 B represents oxygen, sulphur or N-R<sup>3</sup>;  
 R<sup>1</sup> represents -CH<sub>2</sub>.CHR<sup>4</sup>.NR<sup>6</sup>R<sup>7</sup> or a group of  
 formula

5



in which the broken line represents an optional chemical bond;

15 R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup> and R<sup>7</sup> independently represent hydrogen or C<sub>1-6</sub> alkyl;

R<sup>x</sup> and R<sup>y</sup> independently represent hydrogen, hydrocarbon or a heterocyclic group, or R<sup>x</sup> and R<sup>y</sup> together represent a C<sub>2-6</sub> alkylene group;

20 R<sup>z</sup> represents hydrogen, hydrocarbon or a heterocyclic group;


T represents oxygen, sulphur or a group of formula =N.G; and

25 G represents hydrocarbon, a heterocyclic group or an electron-withdrawing group.

2. A compound as claimed in claim 1 represented by formula IIA, and salts and prodrugs thereof:

30

- 35 -



(III A)

wherein

10 one of X<sup>1</sup> and Y<sup>1</sup> represents nitrogen and the other represents A<sup>1</sup>-C;

Z<sup>1</sup> represents oxygen or sulphur;

n is zero, 1, 2 or 3;

B<sup>1</sup> represents oxygen, sulphur or N-R<sup>13</sup>;

15 A<sup>1</sup> represents C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, C<sub>3-7</sub> cycloalkyl, aryl, aryl(C<sub>1-6</sub>)alkyl, C<sub>3-7</sub> heterocycloalkyl, heteroaryl, heteroaryl(C<sub>1-6</sub>)alkyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkylthio, C<sub>1-6</sub> alkylamino or di(C<sub>1-6</sub>)alkylamino, any of which groups may be optionally substituted; or hydrogen, halogen, cyano, trifluoromethyl or amino; and

20 R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>16</sup> and R<sup>17</sup> independently represent hydrogen or C<sub>1-6</sub> alkyl.

25 3. A compound as claimed in claim 1 selected from:

3-(2-aminoethyl)-5-[(3-methyl-1,2,4-thiadiazol-5-yl)aminomethyl]-1H-indole;

3-[2-(dimethylamino)ethyl]-5-[(5-methyl-1,3,4-thiadiazol-2-yl)aminomethyl]-1H-indole;

30 and salts and prodrugs thereof.

4. A pharmaceutical composition comprising a compound as claimed in any one of the preceding claims in

- 36 -


association with a pharmaceutically acceptable carrier or excipient.

5. A compound as claimed in any one of claims 1 to 3 for use in therapy.

6. The use of a compound as claimed in any one of claims 1 to 3 for the manufacture of a medicament for the treatment and/or prevention of clinical 10 conditions for which a selective agonist of 5-HT<sub>1</sub>-like receptors is indicated.

7. A process for the preparation of a compound as claimed in any one of claims 1 to 3 which 15 comprises:


(A) reacting a compound of formula III:



(III)

wherein W, X, Y, Z, A and E are as defined in claim 1; with a compound of formula IV or a carbonyl-protected form thereof:


- 37 -



(IV)

wherein  $\text{R}^2$  is as defined in claim 1 and  $\text{R}^{11}$  corresponds to the group  $\text{R}^1$  as defined in claim 1 or represents a group of formula  $-\text{CH}_2 \cdot \text{CHR}^4 \text{D}^1$ , in which  $\text{R}^4$  is as defined in claim 1 and  $\text{D}^1$  represents a readily displaceable group; followed, where required, by N-alkylation by standard methods to introduce the moiety  $\text{R}^3$ ; or

(B) the cyclisation of a compound of formula  
15 X:




(X)

wherein  $\text{W}$ ,  $\text{X}$ ,  $\text{Y}$ ,  $\text{Z}$ ,  $\text{A}$ ,  $\text{E}$  and  $\text{R}^1$  are as defined in claim 1, and  $\text{D}^3$  represents a readily displaceable group; followed, where required, by N-alkylation by standard methods to introduce the moiety  $\text{R}^3$ ; or

30

(C) reacting a compound of formula XIII:

- 38 -




(XIII)

10 wherein W, X, Y, Z and A are as defined in claim 1, and L represents a suitable leaving group; with a compound of formula  $\text{H}_2\text{N}-\text{E}-\text{F}$ , in which E and F are as defined in claim 1; or

15 (D) reacting a compound of formula  $\text{OHC}-\text{E}'-\text{F}$ , wherein F is as defined in claim 1 and  $\text{E}'$  represents a bond or a straight or branched alkylene chain containing from 1 to 3 carbon atoms, with a compound of formula VIII:

20




(VIII)

wherein W, X, Y, Z and A are as defined in claim 1; followed by treatment with a reducing agent; or

(E) cyclising a compound of formula XIV:

- 39 -



(XIV)

wherein W, X, Y, Z, A, E and R<sup>2</sup> are as defined in claim 1, B' represents oxygen or sulphur, and R<sup>21</sup> corresponds to the group R<sup>1</sup> as defined in claim 1 or represents a precursor group thereto; followed, where required, by conversion of the group R<sup>21</sup> into the desired group R<sup>1</sup> by conventional means; and

15

(F) subsequently, where required, converting a compound of formula I initially obtained into a further compound of formula I by conventional methods.

20

8. A method for the treatment and/or prevention of clinical conditions for which a selective agonist of 5-HT<sub>1</sub>-like receptors is indicated, which method comprises administering to a patient in need of such treatment an effective amount of a compound of formula I as defined in claim 1, or a pharmaceutically acceptable salt thereof or a prodrug thereof.

25

## INTERNATIONAL SEARCH REPORT

PCT/GB 93/00789

International Application No

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all)<sup>6</sup>

According to International Patent Classification (IPC) or to both National Classification and IPC

Int.Cl. 5 C07D417/12; C07D413/12; A61K31/42; A61K31/425  
A61K31/41

## II. FIELDS SEARCHED

Minimum Documentation Searched<sup>7</sup>

Classification System	Classification Symbols
Int.Cl. 5	C07D ; A61K

Documentation Searched other than Minimum Documentation  
to the Extent that such Documents are Included in the Fields Searched<sup>8</sup>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup>

Category <sup>10</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
Y	EP,A,0 438 230 (MERCK SHARP & DOHME LTD.) 24 July 1991 *whole document*	1-7
P,Y	EP,A,0 497 512 (MERCK SHARP & DOHME) 5 August 1992	1-7
P,Y	EP,A,0 494 774 (MERCK SHARP & DOHME) 15 July 1992	1-7
Y	EP,A,0 225 726 (GLAXO GROUP LIMITED) 16 June 1987	1-7
Y	WO,A,9 118 897 (THE WELLCOME FOUNDATION LIMITED) 12 December 1991	1-7
		-/-

<sup>10</sup> Special categories of cited documents :<sup>10</sup>

- <sup>"A"</sup> document defining the general state of the art which is not considered to be of particular relevance
- <sup>"E"</sup> earlier document but published on or after the international filing date
- <sup>"L"</sup> document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- <sup>"O"</sup> document referring to an oral disclosure, use, exhibition or other means
- <sup>"P"</sup> document published prior to the international filing date but later than the priority date claimed

- <sup>"T"</sup> later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- <sup>"X"</sup> document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step
- <sup>"Y"</sup> document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- <sup>"A"</sup> document member of the same patent family

## IV. CERTIFICATION

Date of the Actual Completion of the International Search

28 JUNE 1993

Date of Mailing of this International Search Report

14. 07. 93

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer

SCRUTON-EVANS I.

## III. DOCUMENTS CONSIDERED TO BE RELEVANT

(CONTINUED FROM THE SECOND SHEET)

Category	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
A	EP,A,0 313 397 (THE WELLCOME FOUNDATION LIMITED) 26 April 1989 ----	1-7
A	US,A,4 785 016 (GLAXO GROUP LIMITED) 15 November 1988 ----	1-7
A	EP,A,0 328 200 (MERCK SHARP & DOHME) 16 August 1989 ----	1-7

**ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO.**

GB 9300789  
SA 73118

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 28/06/93

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A-0438230	24-07-91	AU-A-	6944091	25-07-91
		CN-A-	1053429	31-07-91
EP-A-0497512	05-08-92	AU-A-	1068092	06-08-92
		CN-A-	1064485	16-09-92
EP-A-0494774	15-07-92	CA-A-	2058805	12-07-92
		JP-A-	5039290	19-02-93
		US-A-	5208248	04-05-93
EP-A-0225726	16-06-87	JP-A-	62167761	24-07-87
		US-A-	4833153	23-05-89
WO-A-9118897	12-12-91	AU-A-	7957091	31-12-91
		EP-A-	0486666	27-05-92
		JP-T-	5502679	13-05-93
EP-A-0313397	26-04-89	AU-A-	2418188	27-04-89
		JP-A-	1146882	08-06-89
US-A-4785016	15-11-88	AU-B-	584142	18-05-89
		AU-A-	5070585	12-06-86
		BE-A-	903778	03-06-86
		CH-A-	667647	31-10-88
		DE-A-	3542698	05-06-86
		FR-A-	2574077	06-06-86
		GB-A,B	2168973	02-07-86
		JP-A-	61158960	18-07-86
		NL-A-	8503337	01-07-86
		SE-A-	8505715	05-06-86
EP-A-0328200	16-08-89	AU-A-	2986089	17-08-89
		JP-A-	1268687	26-10-89
		US-A-	4952587	28-08-90
		US-A-	5041456	20-08-91